| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a6b928fbe43101d5c4203929fcf8d71 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B29L2031-753
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B29K2083-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B29K2105-0035 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F6-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B29C45-7207
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F6-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B29C45-0001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0036
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F6-14 |
| filingDate |
2009-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d83b332decede999ddbdf9bd175b4ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20b8dd308009c6027613cb2faa8931f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_435e06789e2bad09fed19e7f19d6893e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44131556b0447ab58b0269a46b8fe800 |
| publicationDate |
2012-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
NZ-587758-A |
| titleOfInvention |
Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
| abstract |
Disclosed is the use of: (a) a therapeutically effective amount of progesterone; (b) a polysiloxane elastomer; and (c) a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid in the preparation of a medicament for treating a luteal phase defect in a patient, wherein said medicament is a monolithic intravaginal ring comprising said therapeutically effective amount of progesterone, said polysiloxane elastomer and said pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid, and wherein the polysiloxane elastomer is present in a concentration of about 55% to about 90% by total weight of the ring. |
| priorityDate |
2008-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |